For the year ending 2025-12-31, DNA made $170,155K in revenue. -$309,106K in net income. Net profit margin of -181.66%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue | 170,155 | 227,043 | ||
| Cost of revenue-Service | 31,521 | - | ||
| Cost of revenue-Product | 0 | - | ||
| Cost of revenue-Product And Service Other | 15,451 | - | ||
| Research and development | 243,773 | 424,061 | ||
| General and administrative | 183,290 | 246,161 | ||
| Cost of revenue | - | 38,549 | ||
| Impairment of lease assets | 0 | - | ||
| Goodwill impairment | 0 | 47,858 | ||
| Restructuring charges | 11,398 | 24,172 | ||
| Total operating expenses | 485,433 | 786,800 | ||
| Loss from operations | -315,278 | -559,757 | ||
| Interest income | 22,616 | 38,612 | ||
| Interest expense | 0 | 94 | ||
| Loss on equity method investments | 0 | - | ||
| Loss on investments | -16,411 | -28,827 | ||
| Loss on deconsolidation of subsidiaries | 0 | -7,013 | ||
| Change in fair value of warrant liabilities | 0 | -5,701 | ||
| Other (expense) income, net | -4,527 | 3,870 | ||
| Total other income (expense) | 1,678 | 12,249 | ||
| Loss before income taxes | -313,600 | -547,508 | ||
| Income tax benefit | -837 | -479 | ||
| Net loss | - | -547,029 | ||
| Net loss | -312,763 | -547,029 | ||
| Foreign currency translation adjustment | 3,531 | - | ||
| Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary | 0 | - | ||
| Unrealized gain on available-for-sale securities | -126 | - | ||
| Total other comprehensive income (loss) | 3,657 | - | ||
| Comprehensive loss | -309,106 | - | ||
| Basic EPS | -5.64 | -10.54 | ||
| Diluted EPS | -5.64 | -10.54 | ||
| Basic Average Shares | 55,457,676 | 51,894,639 | ||
| Diluted Average Shares | 55,457,676 | 51,894,639 | ||
Ginkgo Bioworks Holdings, Inc. (DNA)
Ginkgo Bioworks Holdings, Inc. (DNA)